# Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

Study · id `cardio:ct-nct06187311` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06187311](<https://clinicaltrials.gov/study/NCT06187311>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06187311

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 940 participants.

## Technical summary

Registry record NCT06187311. Randomized; no masking; primary purpose treatment. Start 2023-01-12 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 940 participants (planned count; ClinicalTrials.gov record NCT06187311, source copy `cardio:ctgov-nct06187311-2024-01-05`, retrieved 2026-10-26)
- Started: 2023-01-12 (actual) (ClinicalTrials.gov record NCT06187311, source copy `cardio:ctgov-nct06187311-2024-01-05`, retrieved 2026-10-26)
- Primary completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT06187311, source copy `cardio:ctgov-nct06187311-2024-01-05`, retrieved 2026-10-26)
- Completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT06187311, source copy `cardio:ctgov-nct06187311-2024-01-05`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06187311, source copy `cardio:ctgov-nct06187311-2024-01-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06187311-2024-01-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
- Acronym: REVISE-AF
- Condition: Atrial Fibrillation
- Condition: Anticoagulant Adverse Reaction
- Intervention (Drug): Rivaroxaban 20 MG
- Intervention (Drug): Rivaroxaban 15 MG
- Lead sponsor: Korea University Anam Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Korea University Anam Hospital (`cardio:org-korea-university-anam-hospital`)

## Provenance

Content hash: 3607e6ac854b2ec2ab9a906150471ec7e31b1819a09ea697cf96f0f80683aff3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
